NSTG NanoString Technologies

NanoString to Release Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 7, 2018

NanoString to Release Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 7, 2018

SEATTLE, July 09, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release second quarter 2018 financial results after the close of trading on Tuesday, August 7, 2018. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.

Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 5267568. To listen to a live webcast, please visit the investor relations section of the company’s website at .

A replay of the call will be available beginning August 7, 2018 at 7:30pm ET through midnight on August 14, 2018. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 5267568. The webcast will also be available on the Company’s website for one year following the completion of the call.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit .

Contact:

Doug Farrell

Vice President, Investor Relations & Corporate Communications



Phone: 206-602-1768

EN
09/07/2018

Underlying

NSTGNanoString Technologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NanoString Technologies

 PRESS RELEASE
Free
NSTG NanoString Tech...

NanoString Reports Inducement Grants Under Nasdaq Listing Rules

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on December 6, 2023, the Compensation and Human Capital Committee of NanoString’s Board of Directors approved the grant of, in the aggregate, 34,925 restricted stock units, or RSUs, as material inducements to the 10 employees entering into employment with NanoString. One-third of the R...

January 5, 2024 1 EN
 PRESS RELEASE
Free
NSTG NanoString Tech...

NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Health...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, January 10, at 5:15pm ET. Interested parties can access the live webcast from the investor section of the company’s website at . The webcast replay will be available one hour after the conc...

January 4, 2024 1 EN
 PRESS RELEASE
Free
NSTG NanoString Tech...

NanoString Comments on Delaware District Court Verdict

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty. “We respectfully disagree with the jury’s verdict, which we will seek to have overturned or amend...

November 19, 2023 1 EN
 PRESS RELEASE
Free
NSTG NanoString Tech...

NanoString to Webcast Presentations from Upcoming Healthcare Conferenc...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. Stifel 2023 Healthcare Conference Tuesday, November 14th Tom Bailey, NanoString’s chief financial officer, and Doug Farrell, VP of Investor Relations, will participate in a fireside discussion hosted by Stifel analyst Dan Arias at 9:45am ET. Jefferies London Healthcare Conference Thursday, November 16th Tom Bailey, Nano...

November 9, 2023 1 EN
 PRESS RELEASE
Free
NSTG NanoString Tech...

NanoString Technologies Releases Operating Results for Third Quarter o...

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. “The last few months have been extraordinarily productive for our team. During the third quarter, we delivered record revenue whi...

November 6, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch